We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.04%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$2.01M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$805K |
| 2 |
Halliburton
HAL
|
+$792K |
| 3 |
Caterpillar
CAT
|
+$787K |
| 4 |
Steel Dynamics
STLD
|
+$775K |
| 5 |
Booking.com
BKNG
|
+$775K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$1.05M |
| 2 |
Vulcan Materials
VMC
|
+$1.01M |
| 3 |
CoStar Group
CSGP
|
+$998K |
| 4 |
Eli Lilly
LLY
|
+$967K |
| 5 |
Ingersoll Rand
IR
|
+$913K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Denali Therapeutics
DNLI
$3.79B
| $62.8K | 0.04% |
3,045
-304
| -9% | -$7.71K |
|
402
AbCellera Biologics
ABCL
$1.65B
| $61.6K | 0.04% |
13,385
-1,329
| -9% | -$8.09K |
|
|
AGEN
403
Agenus
AGEN
$276M
| $61.1K | 0.04% |
2,702
-269
| -9% | -$7.63K |
|
404
Edgewise Therapeutics
EWTX
$4.28B
| $59.5K | 0.04% |
10,384
-1,038
| -9% | -$7.06K |
|
405
Mineralys Therapeutics
MLYS
$2.32B
| $59K | 0.04% |
6,205
-612
| -9% | -$7.98K |
|
406
ImmunityBio
IBRX
$7.15B
| $58.2K | 0.04% |
34,461
-3,427
| -9% | -$6.88K |
|
407
Protagonist Therapeutics
PTGX
$8.55B
| $57.4K | 0.03% |
3,440
-346
| -9% | -$6.71K |
|
408
4D Molecular Therapeutics
FDMT
$502M
| $57K | 0.03% |
4,479
-444
| -9% | -$7.43K |
|
409
Madrigal Pharmaceuticals
MDGL
$12.6B
| $56.7K | 0.03% |
388
-36
| -8% | -$6.78K |
|
410
Viridian Therapeutics
VRDN
$2.2B
| $54.8K | 0.03% |
3,572
-358
| -9% | -$6.83K |
|
411
Kymera Therapeutics
KYMR
$8.66B
| $53.3K | 0.03% |
3,837
-378
| -9% | -$7.6K |
|
412
Iovance Biotherapeutics
IOVA
$2.04B
| $51.9K | 0.03% |
11,405
-1,137
| -9% | -$7.42K |
|
|
RNAM
413
DELISTED
Avidity Biosciences
RNAM
| $51.8K | 0.03% |
8,113
-807
| -9% | -$6.95K |
|
414
ALX Oncology
ALXO
$262M
| $51.5K | 0.03% |
10,727
-1,067
| -9% | -$5.79K |
|
415
Arcutis Biotherapeutics
ARQT
$3.48B
| $49.1K | 0.03% |
9,248
-924
| -9% | -$7.86K |
|
416
Viking Therapeutics
VKTX
$3.88B
| $48.9K | 0.03% |
4,418
-439
| -9% | -$6.28K |
|
|
ALLK
417
DELISTED
Allakos
ALLK
| $45.8K | 0.03% |
20,177
-2,014
| -9% | -$7.48K |
|
418
Design Therapeutics
DSGN
$751M
| $43.2K | 0.03% |
18,313
-1,824
| -9% | -$8.51K |
|
|
TERN
419
DELISTED
Terns Pharmaceuticals
TERN
| $42.3K | 0.03% |
8,404
-835
| -9% | -$5.3K |
|
420
Lyell Immunopharma
LYEL
$318M
| $42.1K | 0.03% |
1,433
-143
| -9% | -$6.79K |
|
421
Fate Therapeutics
FATE
$275M
| $38.6K | 0.02% |
18,216
-1,809
| -9% | -$5.99K |
|
422
Seres Therapeutics
MCRB
$45M
| $38.5K | 0.02% |
808
-80
| -9% | -$6.11K |
|
|
MORF
423
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $37.9K | 0.02% |
1,654
-164
| -9% | -$8.61K |
|
424
Vir Biotechnology
VIR
$1.46B
| $35.6K | 0.02% |
3,802
-377
| -9% | -$5.38K |
|
425
Biomea Fusion
BMEA
$88.2M
| $35K | 0.02% |
2,543
-252
| -9% | -$4.54K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, Virtus ETF Advisers held 488 positions worth $165M, down 2.4% from $169M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.
Virtus ETF Advisers's Q3 2023 filing shows 53 new, 73 increased, 307 reduced and 54 closed positions. Its largest new stake was Alphabet (Google) Class A: 6,222 shares worth $814K. The largest sale was Netflix, an estimated $1.05M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 28% a quarter earlier, followed by Financials and Technology.
- Virtus ETF Advisers's largest Q3 2023 buy was Alphabet (Google) Class A: 6,222 shares worth $814K.
- Virtus ETF Advisers added most to Coterra Energy in Q3 2023, an estimated $732K increase.
- Virtus ETF Advisers's biggest Q3 2023 reduction was Incyte, cutting an estimated $701K.
- Virtus ETF Advisers fully exited Netflix in Q3 2023, selling an estimated $1.05M.
- Virtus ETF Advisers's ten largest holdings make up 6.1% of its $165M portfolio in Q3 2023.
- Virtus ETF Advisers opened 53 new positions and closed 54 in Q3 2023.
- Virtus ETF Advisers's portfolio value fell 2.4% quarter-over-quarter to $165M.
Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.